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Translational Relevance 
 
Metastatic castrate-resistant prostate cancer (mCRPC) is the most aggressive stage of the disease 
and remains incurable, highlighting the need for new therapeutic targets. Prostate epithelium is 
exquisitely sensitive to MYC activity and accordingly MYC is almost universally overexpressed 
in mCRPC. Unfortunately, the development of therapeutic agents directly targeting MYC has 
been largely unsuccessful, thus emphasizing the indirect targeting of MYC activity through 
inhibition of downstream cellular processes. One of these key processes in cancer cells is to 
accelerate proliferative growth via stimulation of high levels of ribosome biogenesis through 
regulation of RNA polymerase I (Pol I). MYC also regulates and cooperates with PIM kinases to 
increase the activity of the eIF4F translation initiation complex. Here, we provide preclinical 
evidence that co-targeting Pol I transcriptional activity and PIM kinases is an effective means of 
inhibiting MYC-driven prostate cancer. We employ numerous models of PC including a novel 
CRPC patient derived xenograft system which shows the pre-clinical efficacy of therapies that 
combine to target MYC directed signaling to the ribosome. 
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Abstract:  
Purpose: The MYC oncogene is frequently over-expressed in prostate cancer (PC). 
Upregulation of ribosome biogenesis and function is characteristic of MYC-driven tumors. 
Additionally, PIM kinases activate MYC signaling and mRNA translation in PC and cooperate 
with MYC to accelerate tumorigenesis. Here, we investigate the efficacy of a single and dual 
approach targeting ribosome biogenesis and function to treat PC.  
Experimental design: The inhibition of ribosomal RNA (rRNA) synthesis with CX-5461, a 
potent, selective and orally bioavailable inhibitor of RNA polymerase I (Pol I) transcription has 
been successfully exploited therapeutically, but only in models of hematological malignancy. 
CX-5461 and CX-6258, a pan-PIM kinase inhibitor, were tested alone and in combination in PC 
cell lines, in Hi-MYC and PTEN-deficient mouse models and in patient derived xenografts 
(PDX) of metastatic tissue obtained from a castration-resistant PC patient.  
Results: CX-5461 inhibited anchorage-independent growth and induced cell cycle arrest in PC 
cell lines at nanomolar concentrations. Oral administration of 50 mg/kg CX-5461 induced p53 
expression and activity and reduced proliferation (Ki-67) and invasion (loss of ductal actin) in 
Hi-MYC tumors, but not in PTEN null (low MYC) tumors. While 100 mg/kg CX-6258 showed 
limited effect alone, its combination with CX-5461 further suppressed proliferation and 
dramatically reduced large invasive lesions in both models. This rational combination strategy 
significantly inhibited proliferation and induced cell death in PDX of PC.  
Conclusion: Our results demonstrate preclinical efficacy of targeting the ribosome at multiple 
levels and provide a new approach for the treatment of PC. 
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Introduction  
One-in-seven men will be diagnosed with prostate cancer (PC) in their lifetime and PC related 
deaths is above twenty thousand per year in the US (1). PC is driven by androgen receptor (AR) 
activation, making androgen deprivation therapy (ADT) the mainstay of treatment for men with 
advanced PC. Despite initial efficacy, patients inevitably relapse despite castrate levels of serum 
testosterone, a lethal condition known as castrate-resistant prostate cancer (CRPC) (1, 2). 
Targeted therapies to manage PC are limited to AR signaling, although recent clinical trials are 
assessing the therapeutic efficacy of inhibiting the PI3K/mTORC1 pathway(2). Overexpression 
of the MYC oncogene is among the most common alterations in PC, with over 30 percent of 
localized and a majority of CRPC tumors showing MYC overexpression (3, 4). MYC controls 
cell growth by transcriptionally upregulating components involved in ribosome biogenesis, 
including direct binding to ribosomal RNA (rRNA) genes, which hyper-activates the synthesis of 
rRNA (5-7).  
In PC, MYC expression positively correlates with the overexpression of rRNA (8). Additionally, 
the PIM kinases, consisting of three paralogs (PIM1, 2, 3) with pro-oncogenic activities, were 
shown to be concurrently over-expressed with MYC in PC (9). PIM kinases increase MYC 
transcriptional activity (10) and stability (11), they also stimulate eIF4E-dependent mRNA 
translation through stimulation of 4E-BP1 phosphorylation at serine 65 (12). This accelerates 
prostate tumor growth and mediates resistance to conventional therapies (13-15). It has been 
documented that MYC-driven hematological cancers are sensitive to inhibition of eIF4E-
dependent mRNA translation (16). Therefore, we hypothesized that targeting ribosome 
biogenesis and function by inhibiting Pol I transcriptional activity alone, or in combination with 
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inhibitors or modulators of mRNA translation (such as PIM kinases) may represent a novel 
method of treating MYC-driven PC.  
Here, we demonstrate the efficacy of a novel small molecule inhibitor of Pol I transcription, CX-
5461, in inhibiting growth, colony formation and in inducing cell death in human PC cells. Using 
a genetically engineered mouse model (GEMM) of PC, the Hi-MYC model (17), we demonstrate 
that CX-5461 suppresses tumor progression in vivo. Strikingly, CX-5461 in combination therapy 
with the pan-PIM kinase inhibitor CX-6258, lead to a reversion of Hi-MYC tumors back to high 
grade intraepithelial neoplasia (HGPIN). This correlated with repression of ribosome biogenesis 
(reduced rRNA synthesis) and ribosome function (reduced 4EBP1 phosphorylation). 
Furthermore, and as a proof of principle of promising preclinical efficacy, this combination 
therapy prevented tumor growth in a GEMM of PTEN depletion and a PDX model of aggressive 
high-MYC PC unresponsive to conventional therapy.  
Materials and Methods 
Cell culture  
Authenticated PC-3, DU145 and LNCaP human prostate cell lines were purchased from the 
American Type Culture Collection and cultivated in RPMI supplemented with 10% FBS. BM67 
mouse prostate epithelial cells were generated from PBiCre+/-;Ptenfl/fl mice and validated as 
outlined previously (18). The HM-5 mouse prostate cell line was generated from a 5 month old 
male FVB-Tg(ARR2/Pbsn-MYC) lateral prostate. Briefly, lateral prostate lobes were isolated 
and minced into 5 mm3 pieces and digested at 37ºC for 2 hours in DMEM medium containing 
HEPES and 1 mg/ml collagenase (Sigma-Aldrich, USA). Post-digestion, prostate pieces were 
washed in Phosphate-buffered saline (PBS), then transferred to a 100 mm plasma gas treated 
tissue culture dish (BD Biosciences, USA). Cells were grown in growth medium containing 
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RPMI supplemented with 10% FBS (Invitrogen, USA), human recombinant epithelial growth 
factor (life technologies, USA), Bovine Pituitary Extract (life technologies, USA), Insulin 
(Sigma-Aldrich, USA), Penicillin/Streptomycin (P/S) and 10 nM testosterone (T) (Sigma-
Aldrich, USA) and Y-27632 (Sigma-Aldrich, USA) and the media was replaced every 4 days. 
Colonies were isolated then maintained in RPMI containing 5% FBS, P/S and 10 nM T and kept 
in a humidified incubator at 37ºC with 5% CO2. 
Inhibitors 
CX-5461 and CX-6258 were generous gifts from Cylene Pharmaceuticals (San Diego, CA). 
RAD001 was purchased from Selleck Chemicals (Houston, TX). 
Anchorage-independent growth assays 
PC3 and DU145 cells were seeded into 6-well plates as single cell suspensions in 0.35% sterile 
low melt agarose (Bioline, USA) on a 0.7% agarose base layer and incubated overnight as 
described previously (19). These plates were then cultured for 3 weeks to allow colony 
suspensions to form. 
Cell cycle analysis 
Seeded PC-3 and DU145 cells were serum starved for 24 hours prior to incubation with 
inhibitors in order to synchronise the cell cycle at G0 phase of the cell cycle. Cells were fixed in 
70% ethanol, stained with Propidium Iodide (PI) and analysed 24 hours after incubation with 
inhibitors on an LSR Fortessa Cell Analyser (BD Biosciences, USA). 
Animal experiments 
Hi-MYC (ARR2pbsn-MYC) mice were obtained from NCI-Frederick, USA and PTEN-deficient 
(PBiCre+/-;PTENfl/fl) mice were obtained from a breeding colony established at the Peter 
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MacCallum Cancer Centre, Australia. Transgenic Hi-MYC female mice were crossed with wild-
type male mice to generate transgenic Hi-MYC male progeny. PBi-Cre transgenic mice (20) 
were crossed with PTEN floxed animals (21) to specifically deplete PTEN within the prostate 
epithelium. Animals were maintained on a pure FVB/N background. Both Hi-MYC and PTEN 
mice were aged to 4 months and given oral doses of inhibitor, bi-weekly over 4 weeks (9 doses). 
For acute experiments, a single dose of inhibitor was administered over 24 hours. All Hi-MYC 
and PTEN-deficient animals were humanely killed at 5 months of age, 24 hours after the final 
dose of inhibitor. 
Histology & immunohistochemistry (IHC) 
Lateral prostate lobes were isolated from animals 24 hours post therapy and fixed in formalin for 
48 hours before histological processing. Entire prostate lobes were sectioned at 5 µm thick and 
every 20th section was stained with hematoxylin & eosin (H&E) (Dako, Denmark) to visualise 
pathological progression of disease and tumor foci. These sections were scored for percentage of 
invasive lesions by at least two experimenters blind to the genotype and treatment groups. 
Following antigen retrieval, sections were incubated with primary antibody.  Primary antibody 
dilutions are as follows; MYC (1:600 (1 hr), Abcam (Y69)), Ki67 (1:400 (1 hr), Leica 
Biosystems), α-Smooth Muscle Actin (α-SMA) (1:10,000, Sigma), Phospho-ribosomal protein 
S6 (p-rpS6) (1:3000, Cell Signaling). Following washing, sections were incubated in Dako 
Envision goat α-mouse or goat α-rabbit immunoglobulins as appropriate for 1 hour at room 
temperature (Dako, Denmark). Staining was then visualised with choromogen DAB (Di-amino 
benzidene) (Dako, Denmark) for up to 5 minutes before counterstaining with hematoxylin. 
Stained slides were digitised using an Aperio AT Turbo slide scanner (Leica biosystems, USA). 
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Positively stained cells were quantified with counting algorithms provided by Aperio Image 
Scope analysis software (Leica Biosystems, USA)  
Western blotting 
Protein extracts were isolated by lysis in passive lysis buffer solution (Progen, USA).   Whole 
animal prostate lobe tissues were ground into a powder in liquid nitrogen using a pre-chilled 
mortar and pestle and protein lysates were prepared by dissolving the powdered tissue in SDS 
lysis buffer. A detailed description is provided in supplemental methods.  
Ribosomal RNA extraction and q-PCR 
Isolated prostate lobes were snap frozen and maintained at -80ºC until analysed. Tissue was 
homogenised by crushing in liquid nitrogen, then cells were lysed and the RNA extracted using 
then NucleoSpin kit (Macherey-Nagel, Germany). SuperScript III Reverse Transcriptase 
(Thermo Fisher, USA) was used to synthesise cDNA from 1 ug of RNA/sample. The qPCR 
reactions were performed with Fast SYBR-Green Master Mix (Applied Biosystems, USA) on the 
StepOnePlus Real-Time PCR Instrument (Applied Biosystems, USA). Expression of both the 
45S pre-rRNA and p21 were normalised to housekeeping gene B2M. All primer sets have been 
previously published (22, 23) and are as follows: pre-rRNA for: CCA AGT GTT CAT GCC 
ACG TG; pre-rRNA rev: CGA GCG ACT GCC ACA AAA A; p21 for: AAT ACC GTG GGT 
GTC AAA GC; p21 rev: GTG TGA GGA CTC GGG ACA AT; B2M for: TTC ACC CCC ACT 
GAG ACT GA; B2M rev: GTC TTG GGC TCG GCC ATA. 
Statistical analysis 
Graphpad Prism software was used to generate graphs and perform statistical analyses and 
significance of data. In vitro experiments were performed in triplicate and expressed as a 
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summary of the mean of replicates with standard deviation (SD), unless specified otherwise. 
Histological quantitation of mouse prostate tissue was performed using an Aperio ScanScope 
digital scanner and viewed using ImageScope software (Aperio). 
Animal Ethics 
All animal experiments were performed according to protocols approved by the Monash 
University Animal Ethics Committee, Monash University.  
Patient derived xenografts 
Human tissues were obtained post-mortem during autopsy. Tissue collection was performed 
according to approved Human ethics (Peter MacCallum Cancer Centre). Tumor grafts were 
implanted under the renal capsule of immunodeficient mice (NSG) according to our previously 
published protocol (24) with the following modifications: tissue was sectioned in thin 0.3 mm 
slices using a Krumdieck tissue slicer MD6000 (TSE systems, Germany)  and grafted under the 
renal capsule without adding seminal vesicle mesenchymal cells or prostate fibroblasts. Grafts 
were allowed to establish in testosterone supplemented hosts for a period of 3 weeks prior to 
treatment. Host mice were treated with vehicle or CX-5461/CX-6258 combination and given 4 
doses over 9 days. Mice were humanely killed 24 hours after the last dose and grafts were 
harvested. Grafted tissues were measured, weighed and fixed in 10% formalin for 24 hours prior 
to being processed and embedded in paraffin. 
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Results  
PC cells are sensitive to CX-5461, an inhibitor of RNA Pol I transcriptional activity 
MYC loci amplification is observed in more than 30 percent of PC and MYC protein is almost 
universally overexpressed in metastatic CRPC (4). Accordingly, high levels of MYC protein 
expression are observed in primary human prostate epithelial (HPE) cells isolated from patient 
tissue (HPE-1, HPE-2) and in immortalized PC cells; LNCaP, PC3 and DU145 (Figure 1A). 
Conversely, MYC expression is relatively low in BM67 cells, a murine prostate epithelial cancer 
cell line isolated from the PB-Cre;PTENFlox mouse model of PC (Figure 1A, S1A) (18). HM-5 
cells isolated from the Hi-MYC PC mouse model (18) express high levels of MYC (Figure 1A, 
S1A). To determine if inhibition of Pol I transcription has therapeutic potential in PC, we tested 
the ability of CX-5461 to suppress anchorage-independent growth of PC cells in culture. PC3 
and DU145 cells, which are derived from aggressive metastatic PC, form colonies when seeded 
in soft agar. Cells were treated with increasing concentrations of CX-5461. While a 50 nM 
concentration did not significantly impair colony formation, 200 nM suppressed the number of 
colonies significantly in both cell lines: by 83% in PC3 (Figure 1B) and 92% in DU145 (n=3, 
P<0.001) (Figure 1C), demonstrating in vitro efficacy of CX-5461 in suppressing anchorage-
independent growth of PC cells. 
To determine if the impairment of colony formation was due to cytotoxic or cytostatic effects of 
CX-5461, we performed cell cycle analysis of PC3, DU145 and LNCaP cells treated with 
increasing concentrations of CX-5461 (Figure 1D-F). Treatment of PC3 (Figure 1D) and DU145 
cells (Figure 1E) with concentrations of CX-5461 ranging from 50 nM to 1000 nM CX-5461 did 
not significantly increase cell death, as measured through sub-G1 content. In PC3 and DU145 
cells, a concentration of 200 nM and 500 nM of CX-5461, respectively, induced a cell cycle 
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arrest characterized by accumulation of cells in G2-M (Figure 1D-E). However, LNCaP cells 
were 7 to 15 times more sensitive to CX-5461 than PC3 and DU145 cells, respectively (Figure 
1F), with a 30nM concentration sufficient to induce cell cycle arrest and accumulation in G2/M 
phase, again without induction of cell death. One determinant of sensitivity to CX-5461 is p53 
activity (22). Both PC3 and DU145 cells are p53 null while LNCaP cells express functional p53 
(25). Accordingly, phosphorylated p53 accumulation was observed in LNCaP cells at 2 hours 
following treatment with CX-5461 (Figure 1G). This p53 accumulation was also accompanied 
by an increase in p21 at 8 and 24 hours post-treatment (Figure 1G). These results show that CX-
5461 is cytostatic in PC cell lines, arresting cells in G2M. The lack of apoptosis is not simply due 
to the lack of p53 as LNCaP also arrest in G2M despite activating a p53 response.  These data 
are consistent with our earlier studies demonstrating that in solid tumors therapeutic efficacy of 
CX-5461 does not correlate with p53 status (26), but can promote sensitivity when present. 
Together, these results demonstrate that PC cells are sensitive to Pol I transcription inhibition in 
vitro, leading to significant cell cycle arrest that abrogates colony formation. 
RNA polymerase I activity inhibition suppresses tumor progression in MYC-driven prostate 
cancer, in vivo 
In order to evaluate CX-5461 potential to prevent disease progression in vivo, we employed a 
GEMM that faithfully recapitulates human disease progression from PIN to invasive carcinoma. 
GEMM of PC have the advantage of developing autochthonous tumors at high penetrance and 
with reproducible kinetics. To test if the sensitivity of PC cell lines to Pol I transcription 
inhibition would translate to a therapeutic effect in vivo we tested CX-5461 in the Hi-MYC 
mouse (17). The Hi-MYC mouse reproduces the pathological development of human PC. In this 
model, MYC expression is under the control of the probasin promoter, which is prostate-specific 
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and androgen-dependent. Neoplastic lesions develop initially in the ventral and lateral lobes (17). 
High grade intra-epithelial neoplasia (PIN) is observed at 2 months of age; in situ carcinoma is 
fully penetrant at 5 months of age. We followed disease progression at various time points 
(Figure 2A) and our observations show a reproducible and highly penetrant phenotype. At 5 
months of age we observed the development of multiple invasive lesions while, by 8 months, 
invasive lesions occupied most of the ventral and lateral lobes (Figure 2A). This is characterized 
by the loss or fragmentation of the smooth muscle actin layer surrounding the prostatic ducts, as 
previously reported (17, 27). Hi-MYC tumors are highly proliferative (17) and quantitation 
shows that 50% of luminal epithelial cells over-express MYC (Figure 2B) with a high 
proliferative index marked by Ki-67. This is evident by 2 months of age, maintained at 5 months 
and then reduced by 8 months as tumors become highly compacted with ductal lumen entirely 
filled with tumor cells (Figure 2B). Considering that proliferation peaks and invasive lesions 
develop at 5 month of age, we selected this time point as the most suitable for determining 
efficacy of Pol I inhibition on proliferation and invasion in this model.  
Five month old Hi-MYC mice (n=3 per group) were treated with CX-5461 at a dose of 50 
mg/kg. This dose was previously shown to induce therapeutic effects in a MYC-driven murine 
model of lymphoma (22). Following 24 hours of treatment lateral prostate tissue was isolated 
and analyzed for Pol I transcription rate by measuring the abundance of the 45S pre-ribosomal 
RNA (rRNA) (Figure 2C) and for induction of p53 (Figure 2D), which is a known marker of the 
immediate response to RNA Pol I transcription inhibition in p53 WT tumors in vivo (22). 
Animals treated with CX-5461 for 24 hours displayed a significant reduction (66% ± 26%) in the 
amount of 45S pre-rRNA (Figure 2C) (n=3, P=0.048), which correlated with a robust 
accumulation of p53 in the same tissues (Figure 2D). We then examined the therapeutic effect of 
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a longer term dosage of CX-5461 in Hi-MYC mice. Four-month old Hi-MYC mice were dosed 
twice weekly for 4 weeks, with 50 mg/kg CX-5461 for a total of 9 doses (n=3 per group). At 
sacrifice, lateral prostate tissue was harvested and analyzed by IHC. While the number of MYC 
expressing epithelial cells were not significantly reduced in these tissue sections (Figure 2E, F), 
Ki-67 expression was reduced by 50% (n=3 per group, P=0.024), indicating that the proliferative 
capacity was significantly repressed (Figure 2G, H). This striking reduction in the proliferative 
potential of Hi-MYC tumors confirms the in vivo efficacy of CX-5461 in solid tumors and 
supports the in vitro results obtained with PC cell lines showing cell cycle arrest. 
Co-targeting PIM kinase activity potentiates the effect of RNA polymerase I activity inhibition in 
prostate cancer cells. 
As previously mentioned, PIM-1 is co-elevated with MYC in human and Hi-MYC prostate 
adenocarcinoma, where it is believed to accelerate tumorigenesis (17). It was recently shown that 
resistance to therapy with the mTORC1 inhibitor, RAD001, is mediated by up-regulated 
signaling via eukaryotic initiation factor 4E binding protein-1 (4E-BP1) in Hi-MYC mice (15, 
28), a PIM kinase substrate (29). Additionally, a PIM inhibitor has been reported recently to have 
efficacy in a model of MYC-driven prostate cancer (30). We therefore examined whether 
suppressing ribosome biogenesis with CX-5461 and PIM kinase activity co-operate in PC 
inhibition. Firstly, we tested the efficacy of CX-6258, a novel pan-PIM inhibitor (31) in 
inhibiting anchorage-independent growth of PC3 and DU145 cells. CX-6258 significantly 
suppressed colony formation of PC3 and DU145 cells (n=3, P<0.001) (Figure 3A, B). Cell cycle 
analyses of LNCaP cells 48 hours following CX-6258 treatment revealed a significant decrease 
in G0/G1 phase and a pronounced accumulation of cells in G2/M phase (Figure 3C). Consistent 
with previous studies showing that PIM kinases regulate 4E-BP1, western blotting analysis 
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demonstrated that phosphorylation on serine 65 (S65) of 4E-BP1 was reduced (Figure 3D), along 
with a dramatic shift of hyper-phosphorylated 4E-BP1 (top arrow) to hypo-phosphorylated 
(bottom arrow) total 4E-BP1 within 2 hours of treatment with 5 and 10 μM CX-6258 only and 
not with CX-5461 (Figure 3D). Combined treatment of PC3 and DU145 cells with 50 nM of CX-
5461 and CX-6258 significantly reduced anchorage-independent growth compared to single 
agents (Figure 3E, F). Cell cycle analysis revealed that LNCaP and DU145 cells treated with a 
combination of agents exhibited a significant arrest in G2/M phase than what was observed with 
either agent alone (Figure 3G, H). 
To further examine the potential cooperative effects of combined Pol I transcription inhibition 
and PIM kinase inhibition in the context of MYC driven PC, we generated an epithelial cell line 
from a 5-month old Hi-MYC mouse lateral prostate adenocarcinoma (HM-5) (Figure S1). HM-5 
cells treated with CX-5461 for 4 hours showed a dose-dependent decrease in 45S pre-rRNA 
abundance (n=3, P<0.05) (Figure 4A), which correlated with a robust induction of p53 (Figure 
4B) and the p53 target gene, p21, which mediates cell cycle arrest (Figure 4C). HM-5 cells 
treated with 100 nM CX-5461 for 24 hours showed significant accumulation in G2/M phase 
(Figure 4D). Conversely, HM-5 cells treated with 500 nM of CX-6258 showed a marked 
increase of cells in G0/G1 phase of the cell cycle (n=3, P< 0.01) (Figure 4D), consistent with the 
effects seen with other growth factor signaling pathway inhibitors (32). While the combination of 
inhibitors show significant G2/M accumulation of cells consistent with CX-5461 single agent 
effect. This strongly suggests that, even though PIM suppression via CX-6258 does not initiate 
G2/M arrest alone in these cells, it does not prevent CX-5461 induced G2/M suppression 
indicating that G2/M arrest is dominant. Western blot analysis of HM-5 cells treated with 500 
nM CX-6258 showed a marked reduction in 4E-BP1 phosphorylation at s65 and almost complete 
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suppression at a concentration of 5000 nM CX-6258 (Figure 4E). The combination effect was 
assessed in HM-5 cells by allowing them to proliferate in the presence of low, sub-lethal doses of 
each inhibitor. A concentration of 10 nM CX-5461 was found to co-operate with 200 nM CX-
6258 to reduce the number of cells after 72 hours incubation, significantly more than cells grown 
in the presence of vehicle or either inhibitor alone (Figure 4F). Additionally, this combination 
resulted in a significant reduction in the number of colonies formed as compared with vehicle or 
single agent treated cells (Figure 4G). Viability of HM-5 cells was assessed after 72 hours 
incubation with CX-5461, CX-6258 or in combination and showed that indeed these drugs co-
operate to induce cell death at this concentration (Figure 4H). Together, this data demonstrates 
that combined Pol I transcription inhibition and PIM kinase inhibition co-operates in vitro to 
enhance efficacy of each inhibitor in Hi-MYC tumor cells. 
Co-targeting RNA Pol I and PIM in the Hi-MYC and the PTEN-deficient models of PC 
We next examined whether the robust effect of combining Pol I inhibition with PIM inhibition 
on MYC-driven PC in vitro translated to an improved therapeutic outcome in vivo. To test this, 
four-month old Hi-MYC mice were treated with single agents or combination therapy for 4 
weeks, bi-weekly, and the effect of therapy on lateral prostate adenocarcinoma were analyzed via 
histopathological assessment and IHC with 8-11 animals per treatment group (Vehicle: n=11, 
CX-5461: n=8, CX-6258: n=8, combination: n=11).  
Animals on combination therapy had a markedly improved phenotype, displaying HGPIN as the 
most prevalent lesion compared with vehicle alone or either inhibitor alone (Figure 5A). While 
assessing the occurrence of invasive lesions in the same groups, we observed that CX-5461 alone 
drastically reduced the number of invasive lesions (Figure 5B). There was no striking difference 
in the histopathology of lesions in CX-6258 treated animals compared with animals treated with 
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vehicle only, indicating that inhibiting PIM alone may have limited impact in preventing MYC 
induced adenocarcinoma.  Similar to CX-5461 alone, combination therapy suppressed the 
incidence of invasive foci in almost all treated animals (9/11 animals) (Figure 5B).  In addition, 
cell proliferation, as marked by Ki-67, was significantly lower in animals treated with 
combination therapy as compared with other groups (Figure 5C). These results highlight the fact 
that PIM co-operates with MYC but does not direct MYC oncogenic influence completely. 
Importantly, there was no impact on body weight of animals in any of the treatment groups, 
indicating these drugs were well tolerated in combination (Figure S2) and provide a novel and 
potent therapeutic approach to treat PC. In contrast with these findings, but in agreement with 
results reported by Clegg and colleagues (28), no cooperativity was observed in vivo in Hi-MYC 
mice when combining CX-5461 with RAD001, a partial inhibitor of mTORC1 (Figure S3).  
We then examined whether this robust combination effect could be validated in another GEMM 
of PC by employing the conditional PTEN-KO model (33, 34), where MYC expression is 
comparatively low. Again, four-month old PTEN-deficient mice were treated for 4 weeks, bi-
weekly, and the effect of therapy on anterior prostate carcinoma were analyzed via 
histopathological assessment with 4 animals per treatment group for the total percentage of 
carcinoma. Unlike the Hi-MYC model, we did not observe invasive adenocarcinoma in any 
tissue sections and the highest grade lesion observed was carcinoma in situ (CIS) (Figure 5D) 
which is consistent with previous characterization of this GEMM (33). In contrast with the Hi-
MYC model, we observed no significant histological differences in animals treated with CX-
5461 alone. This difference in response between these two models most likely stems from a 
lower dependence on MYC as a driver of tumorigenesis in the PTEN-deficient mouse and thus 
low levels of MYC do not sensitize these tumors to Pol I inhibition as a single agent. However, 
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we observed a decreased incidence of carcinoma in situ (CIS) in animals treated with CX-6258 
alone and a striking decrease in tumor burden after combination treatment (Figure 5D). Animals 
receiving the combination therapy had a ~50% decrease in incidence of CIS (P=0.03) (Figure 
5E) and displayed HGPIN as their predominant pathology (Figure 5D). These observations are 
consistent with recent evidence that PIM kinases regulate PI3K signaling through indirect 
mTORC1 modulation (35), which could decrease signalling downstream of AKT. Taken 
together these results in GEMM of advanced localised PC demonstrate strong pre-clinical 
efficacy of the benefit of targeting signaling to the ribosome at multiple fronts.    
 Patient derived xenografts from multi-drug resistant CRPC metastasis are sensitive to dual 
inhibition of Pol I and PIM kinases 
The current challenge in the treatment of advanced PC is the progression to late stage disease, 
CRPC and the development of resistance to novel AR targeting agents (36). Having 
demonstrated efficacy of our CX-5461/CX-6258 combination therapy in vitro and the Hi-MYC 
and PTEN-deficient in vivo models of PC, we tested the efficacy of this strategy using metastatic 
PC tissue obtained at autopsy. We used a patient derived xenograft (PDX) model in which thin 
slices of tissue are grafted under the renal capsule of immune deficient host mice. To take into 
account the heterogeneity of tissue during grafting, we devised a procedure (Figure 6A) whereby 
the tissue is sectioned and each contiguous slice is allocated to either a vehicle or drug treatment 
group. Considering, that this PDX approach requires that the whole experiment be done from the 
same starting graft due to tumor heterogeneity, it is not feasible to perform this experiment with 
more than two groups (e.g. vehicle vs. treatment). Using this approach we tested the combination 
of CX-5461 and CX-6258. Following engraftment, tumors were allowed to grow for 3 weeks 
followed by oral dosage over 9 days. Tumors were harvested and weighed (Figure 6B). 
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Comparison of graft weights from paired samples demonstrates a significant inhibition of tumor 
growth in the majority of drug treated samples. In 11 out of 16 pairs, the drug treated tumors had 
a lower weight than the corresponding vehicle treated tumor (Figure 6C) (P=0.04). Percentage of 
Ki-67 (Figure 6D) shows that these treated tumors have lower proliferation than vehicle treated 
pairs and increased cell death as marked by cleaved caspase-3 (Figure 6E). Considering that this 
tissue is derived from a metastasis isolated from a patient who failed to respond to conventional 
therapy and novel androgen targeted therapeutics, this significant result demonstrates the 
efficacy of this combination therapy in lethal PC. 
Discussion  
In this report, we describe the potential of RNA polymerase I transcription inhibition as a therapy 
for MYC-driven PC using a novel compound, CX-5461, in both human cells and GEMMs of PC 
that reflects the progression of human pathology. Pol I inhibition resulted in cell cycle arrest in 
human PC cell lines, even when p53 was mutated or lost, and this was associated with potent 
inhibition of colony formation in p53-null human lines and p53 wild type PC cells from the Hi-
MYC mouse. These findings are consistent with our previous observation that the mutational 
status of p53 does not correlate with cell sensitivity to Pol I inhibition (26); however, it does 
significantly enhance inhibitor sensitivity (6). This is an important finding as loss-of-function 
p53 mutations are among the most common in PC, being present in roughly 50% of cases (37). 
Clegg et al. (28) previously described the resistance of Hi-MYC mice to rapamycin. 
Additionally, Balakumaran et al. described that MYC-driven prostate cancer circumvents 
mTORC1 inhibition induced growth suppression because of incomplete or partial inhibition of 
mTORC1 (38), which most likely sustains or enhances 4EBP1 activity. Additionally, PIM-1 can 
mediate resistance by upregulating receptor tyrosine kinase activity in response to PI3K pathway 
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suppression (15). Although it remains unclear whether PIM kinases also mediate this resistance 
to therapy in Hi-MYC mice, PIM-1 was shown to be among the most significantly upregulated 
oncogenes in PC (17) and we show that significant phosphorylation of 4E-BP1 is observed in our 
Hi-MYC tumor cell line, HM-5, which could be relieved with CX-6258 administration. 
Interestingly, a recent study investigating MYC-driven colorectal tumorigenesis showed that 
targeting translation initiation bypasses this crosstalk signaling between MYC and mTOR 
resulting in reduced MYC levels in cancer (39). 
Acute oral administration of CX-5461 and CX-6258 induced a 42% reduction in proliferative 
index in Hi-MYC adenocarcinoma and a remarkable decrease in the incidence of invasive tumor 
foci. It was recently described that PIM kinase inhibition had shown promising efficacy as a 
single agent in models of MYC-driven PC (30). In contrast, the results of our study do not show 
significant efficacy in a MYC-driven autochthonous PC model. However, the cooperation 
between CX-6258 and CX-5461 is consistent with the data of Kirschner et al., showing that PIM 
kinase inhibition synergises well with agents that induce a p53 response in their mouse model of 
MYC-driven prostate cancer such as docetaxel and radiation therapy, standard therapies for 
recurrent PC (30). PTEN-deficiency is a feature of approximately 40% of PC (37), and here we 
show that this combination is also effective in a low MYC, PTEN deficiency-driven GEMM and 
PDX derived from human mCRPC. This is consistent with our hypothesis that this combination 
approach to targeting the ribosome will be efficacious in cancers featuring dysregulation of 
signalling via PI3K as well as MYC (40). To our knowledge, we are the first group to 
demonstrate that targeting ribosome biogenesis and ribosome function simultaneously can be 
exploited therapeutically in clinically relevant models of PC. 
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The data presented here strongly supports the idea that MYC confers tumor sensitivity to Pol I 
inhibition alone and treatment efficacy is remarkably enhanced when combined with PIM 
inhibition. These findings are significant as they demonstrate that MYC and PIM oncogenes are 
profoundly co-operative in PC and drive cell addiction to ribosome transcription and mRNA 
translation. This work supports the potential treatment of human prostate cancer with novel 
therapeutic agents, especially those resistant to conventional therapy and are characterised by 
MYC amplification. CX-5461 and pan-PIM inhibitors (41) are currently in phase 1 clinical trials 
for hematological malignancy.   
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Figure legends 
Fig. 1. CX-5461 inhibits the anchorage-independent growth of PC cells and induces cell 
cycle arrest independent of p53 status. (A) Western blotting analysis of protein extracts from 
human (HPE-1, HPE-2, PC3, DU145, LNCaP) and mouse (BM67, HM-5) prostate cancer cell 
lines showing MYC expression with β-actin as a loading control. (B) The relative number of 
colonies suspended in low melt agarose of PC-3 and (C) DU145 cells after 3 weeks incubation 
with CX-5461 (red & blue) or vehicle only (black) (mean ± SD, *P<0.0001). (D) The percentage 
of PC-3 and (E) DU145 cells in each cell cycle phase after 24hrs incubation with increasing 
concentrations of CX-5461 (red & blue) or vehicle only (black) (n=3, mean ± SD). (F) The 
percentage of LNCaP cells in each cell cycle phase after 48 hrs incubation with increasing 
concentrations of CX-5461 (green) or vehicle only (black). (G) Western blotting analysis of 
protein extracts from LNCaP cells showing expression of p53 and p21 after 30 min, 2, 4, 8 and 
24 hours after administration of CX-5461. 
Fig. 2. CX-5461 inhibits ribosomal DNA transcription and MYC-driven cell proliferation 
in vivo, in Hi-MYC prostate adenocarcinoma. (A) Representative images of wild type (WT) or 
Hi-MYC lateral prostate from 2, 5 and 8 month old mice, immunohistochemically stained for α-
smooth muscle actin (α-SMA) (Arrows mark fragmented smooth muscle, scale bars = 100 µm) 
(B) The percentage of MYC (upper) and Ki-67 (lower) positive cells analysed by IHC at each 
age described (n=3 per group, mean ± SD, *P <0.05). (C) The relative expression of 45S 
precursor rRNA from 5 month old Hi-MYC lateral prostate (Hi-MYC LP) isolated from mice 0, 
8 and 24 hrs after an oral dose of 50 mg/kg CX-5461 (n=3 per group, mean ± SD, paired t-test 
*P=0.05). (D) The expression of p53 protein in Hi-MYC LP isolated from mice 2, 4, 8, 12 and 
24 hrs after an oral dose of 50mg/kg CX-5461. (E, F) Representative images and (G, H) 
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quantitation of 5 month old Hi-MYC LP showing IHC for MYC and Ki-67 respectively after 
isolation from mice given longer term therapy with CX-5461 (50 mg/kg, bi-weekly, 9 doses, 
Scale bars = 100 µm) (n=3, mean ± SD, t-test *P=0.02). 
Fig. 3. CX-5461 co-operates with pan-PIM kinases inhibitor, CX-6258, in PC cell lines.  
(A) The relative number of colonies suspended in low melt agarose of PC3 and (B) DU145 cells 
after 3 weeks incubation with CX-6258 (red & blue) or vehicle only (black) (mean ± SD, 
*P<0.01, ** P<0.001, *** P<0.0001). (C) The percentage of LNCaP cells in each phase of the 
cell cycle after 48 hrs incubation in the presence of CX-6258 (mean ± SD, **P<0.01, 
****P<0.0001). (D) Western blotting analysis of PC3 and DU145 cell extracts after 2 hours 
incubation with either 0, 5 or 10 μM CX-6258 or 10 μM CX-5461. These blots were probed for 
the expression of MYC, phosphorylated 4E-BP1 (s65), total 4E-BP1 and β-actin (loading 
control).  (E) The relative number of colonies suspended in low melt agarose of PC3 and (F) 
DU145 cells after 3 weeks incubation with a single agent or in combination or vehicle only 
(mean ± SEM, *p<0.01, **p<0.001, ***p<0.0001). The percentage of (G) LNCaP and (H) 
DU145 cells in each phase of the cell cycle after 24 hrs incubation with either single agent alone 
or in combination (*P≤0.05, **P<0.01, ***P<0.001, ****P<0.0001).  
Fig. 4. Combined inhibition induces p53 mediated cell cycle arrest and death in a Hi-MYC 
tumor cell line. (A) The relative abundance of 45S pre-rRNA as marked by 5’ Internal 
transcribed spacer 1 (ITS1) after 1 hr incubation with CX-5461 in a 5 month old Hi-MYC tumor 
cell line (HM-5) (mean ± SD, ANOVA **P<0.01, ****P<0.0001). (B) Western blotting analysis 
showing the expression of p53 after 1hr incubation with increasing doses of CX-5461 in HM-5 
cells. (C) The relative abundance of p21 mRNA after 1 hr incubation with increasing doses of 
CX-5461 (mean ± SD, ANOVA *P<0.05 **P<0.01 ***P<0.001). (D) The number of cells in 
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each phase of the cell cycle after incubation with either CX-5461, CX-6258 or in combination 
for 24 hrs (mean ± SD, ANOVA *P≤0.05). (E) Western blotting analysis of the change in MYC, 
PIM-1, phosphorylated 4E-BP1 (s65), total 4E-BP1 and β-actin (loading control) expression 
after 2 hrs incubation with increasing doses of CX-6258. (F) The relative number of cells after 
incubation with 10 nM CX-5461, 200 nM CX-6258 or a combination of inhibitors for 72 hrs 
(mean ± SD, ANOVA *p<0.05 **p<0.01). (G) The relative number of colonies suspended in 2% 
matrigel after incubation with CX-5461, CX-6258 or a combination of inhibitors (mean ± SD, 
ANOVA *p<0.05). (H) The percentage of dead cells after 72hrs incubation with a single dose of 
CX-5461, CX-6258 or in combination (mean ± SD, ANOVA *p<0.05 **p<0.01). 
Fig. 5 CX-5461 co-operates with pan-PIM kinases inhibitor CX-6258, in vivo, to inhibit 
proliferation and incidence of invasive carcinoma. (A) Representative images at low (4X) and 
high (10X) magnification of α-smooth muscle actin (α-SMA) IHC of 5 month old Hi-MYC mice 
orally dosed with either Vehicle (n=11), CX-5461 (n=8), CX-6258 (n=8) single agents alone or 
in combination (n=11) (bi-weekly, 9 doses). Arrows mark fragmented smooth muscle actin. 
Scale bars = 100 µm (B) The percentage of invasive lesions in Hi-MYC LP as a proportion of 
total lesions (invasive & non-invasive) marked by the loss of α-SMA. Each point represents an 
individual mouse, blindly quantified for lesions. (C) The percentage of cells positive Ki-67 in 
representative Hi-MYC lateral prostate sections (mean difference analysed by ANOVA, 
Dunnett’s post hoc, *P<0.05). (D) Representative images of low (2X) and high (20X) 
magnification of 5 month old anterior prostate from PTEN deficient (PBiCre+;PtenFl/Fl) mice 
dosed with either Vehicle (n=4), CX-5461 (n=4), CX-6258 (n=4) or in combination (n=4) (bi-
weekly, 9 doses). (E) The percentage of in situ carcinoma in these mice 24 hours after final 
dosage. Each point represents an individual mouse. 
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Fig. 6 Combination therapy inhibits tumor growth in high-MYC mCRPC patient-derived 
xenografts. (A) The PDX technique involves cutting the tissue into thin slices (0.3 mm) using an 
automated live tissue microtome and regrafting slices across all recipient mice, noting the 
numerical order of each slice and the position of the graft on each kidney. For each drug 
treatment, a minimum of 8 mice is required (4 vehicle and 4 controls). Tumors were allowed to 
grow on the kidney of NSG recipient mice for 3 weeks before drug treatment via gavage for 2 
weeks. At time of collection, the volume of each harvested graft is measured with a calliper and 
also weighed. (B) Graphical analysis is plotted as contiguous tumors generated from the original 
graft. Impact of tumor growth is analysed by comparing the weight of each drug combination 
treated graft to the previous vehicle-only treated graft in sequential order of sectioned slices. This 
approach allows us to control for heterogeneity or polyclonality in the precursor tumor. (C) 
Differences in weight obtained from graft pairs (drug treated vs. vehicle) from contiguous slices. 
(*P=0.04). (D) Differences in Ki-67 (p<0.001) and (E) cleaved caspase-3 (p=0.02) percentage 
between graft pairs (drug treated vs. vehicle) from contiguous slices. Statistical analysis is 
performed using the Wilcoxon signed-rank test for paired observations (contiguous tissue slices). 
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